Results 231 to 240 of about 36,802 (283)

Mathematical modeling of <i>JAK2V617F</i> clonal expansion in a general population cohort. [PDF]

Proc Natl Acad Sci U S A
Snyder J, Andersen M, Gudmand-Høyer J, Larsen MK, Skov V, Kjær L, Eickhardt-Dalbøge CS, Knudsen TA, Ellervik C, Hasselbalch HC, Ottesen JT, Stiehl T.   +11 more
europepmc   +1 more source

Development and validation of a quantitative method for the enumeration of <i>Salmonella enterica</i> serovar Infantis from environmental poultry feces based on most probable number approach followed by confirmatory qPCR. [PDF]

Front Microbiol
Ricchi M, Pezzolato R, Filippi A, Fabbrocino E, Mantovani L, Perulli S, Cirasella L, Luppi A, Tosi G.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN

International Review of Cell and Molecular Biology, 2022
Myeloproliferative neoplasms (MPN) have an inherent tendency to evolve to the blast phase (BP), characterized by ≥20% myeloblasts in the blood or bone marrow. MPN-BP portends a dismal prognosis and currently, effective treatment modalities are scarce, except for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in selected patients ...
Helen T Chifotides, Prithviraj Bose, Srdan Verstovšek   +2 more
exaly   +3 more sources

Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG)

Blood, 2013
Abstract Background We have previously reported on the high prevalence and severity of challenges with intimacy and sexuality amongst a large international cohort of MPN patients (Emanuel JCO 2012). We sought to further analyze the relationships between issues of intimacy (sexual desire and function),
H.L., Geyer, A.C., Dueck, R.M., Emanuel, K., Cannon, J.-J., Kiladjian, S., Slot, S., Zweegman, P., Boekhorst, S., Commandeur, H.C., Schouten, F., Sackmann, A.K., Fuentes, D., Hernandez, H.L., Pahl, M., Griesshammer, F., Stegelmann, K., Döhner, T., Lehmann, D., Ranta, A., Reiter, F., Boyer, G., Etienne, J.-C., Ianotto, L., Roy, J.-Y., Cahn, C.N., Harrison, D.H., Radia, P.J., Muxi, N.I., Maldonado, C., Besses, F., Cervantes, P., Johansson, T., Barbui, G., Barosi, A.M., Vannucchi, F., Passamonti, B., Andreasson, M., Ferrari, A., Rambaldi, J., Samuelsson, G., Birgegard, Z., Xiao, Z., Xu, X., Sun, J., Xu, P., Zhang, R.P., Gale, R.A., Mesa   +47 more
openaire   +5 more sources

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN

Cytometry Part B - Clinical Cytometry, 2021
The proliferation marker Ki-67 is widely used within the field of diagnostic histopathology as a prognostic marker for solid cancers. However, Ki-67 is hardly used for prognostic and diagnostic purposes in flow cytometric analyses of hematologic ...
Mathie Leers, Stefan Mestrum
exaly   +2 more sources

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry [PDF]

Journal of Hematology and Oncology, 2016
Background: Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are at increased risk for thrombosis/thromboembolism and major bleeding. Due to the
Steffen Koschmieder, E Jost
exaly   +2 more sources

Lab tests for MPN

2022
Molecular laboratory investigations for myeloproliferative neoplasm (MPN) can ideally be divided into two distincts groups, those for the detection of the BCR-ABL rearrangement (suspect of chronic myeloid leukemia) and those for the variants determination of the driver genes of the negative Philadelphia forms (MPN Ph neg).
Alice, Moncada, Alessandro, Pancrazzi
openaire   +2 more sources

Management of Myeloproliferative Neoplasms (MPNs)

Journal of Oncology Pharmacy Practice, 2022
Purpose To provide up to date guidance, practice recommendations and highlight barriers to medication adherence in the long-term management of chronic myeloproliferative neoplasms (MPNs). Aim Current drug therapy for MPN is not ...
Zubeir Nurgat, Myer Lawrence
openaire   +2 more sources

Familial MPN Predisposition

Current Hematologic Malignancy Reports, 2017
Chronic myeloproliferative neoplasms (MPN) characteristically arise from a somatic mutation in the pluripotent hematopoietic stem cell, and most common recurring mutations are in the JAK2, CALR, and cMPL genes. However, these mutations are not founder mutations, but mainly drive the disease phenotype and a pre-existing germline predisposition has been ...
Tsewang, Tashi, Sabina, Swierczek, Josef T, Prchal   +2 more
openaire   +2 more sources